Clinical Trial Update: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Clinical trial update noting the completion of a Phase 2 study of XmAb20717 (Vudalimab), as monotherapy or in combination with chemotherapy or targeted therapy,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Vudalimab (XmAb20717)

Snippet

Sponsor: Xencor, Inc. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED